Chiesi said the KalVista deal will bolster Chiesi Global Rare Diseases, it’s business unit marketing therapies in the sector. Credit: Na_Studio/Shutterstock.com. Chiesi has conducted the largest ...

Teva’s Emalex buyout falls under the company's wider strategy of prioritising deals around de-risked, differentiated, late-stage assets.

Regeneron raised GAAP gross margin on net product sales to 79% to 80% from 77% to 78%. Credit: viewimage / Shutterstock.com. Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting ...

The JCA aims to centralise clinical assessment across the EU but tight timelines and stringent evidence requitements have cast doubt over the how fit for purpose the process is. Photo by Mahir Asadli ...

Source is increasing in appeal across clinical research, offering sites and sponsors greater efficiencies in resources as budgets tighten, along with higher levels of precision and quality in data ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Arcera Life Sciences and Fosun Pharma have signed an MoU for a strategic long-term collaboration in the global life sciences industry.

Sun Pharma has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash.

Eli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing.

A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars being spent by the pharma industry to shore up revenue streams amid a looming patent cliff ...

Merck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication.